PT - JOURNAL ARTICLE AU - Kwak, Min Gu AU - Su, Yi AU - Chen, Kewei AU - Weidman, David AU - Wu, Teresa AU - Lure, Fleming AU - Li, Jing TI - Self-Supervised Contrastive Learning to Predict Alzheimer’s Disease Progression with 3D Amyloid-PET AID - 10.1101/2023.04.20.23288886 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.20.23288886 4099 - http://medrxiv.org/content/early/2023/04/26/2023.04.20.23288886.short 4100 - http://medrxiv.org/content/early/2023/04/26/2023.04.20.23288886.full AB - Early diagnosis of Alzheimer’s disease (AD) is an important task that facilitates the development of treatment and prevention strategies and may potentially improve patient outcomes. Neuroimaging has shown great promise, including the amyloid-PET which measures the accumulation of amyloid plaques in the brain – a hallmark of AD. It is desirable to train end-to-end deep learning models to predict the progression of AD for individuals at early stages based on 3D amyloid-PET. However, commonly used models are trained in a fully supervised learning manner and they are inevitably biased toward the given label information. To this end, we propose a self-supervised contrastive learning method to predict AD progression with 3D amyloid-PET. It uses unlabeled data to capture general representations underlying the images. As the downstream task is given as classification, unlike the general self-supervised learning problem that aims to generate task-agnostic representations, we also propose a loss function to utilize the label information in the pre-training. To demonstrate the performance of our method, we conducted experiments on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. The results confirmed that the proposed method is capable of providing appropriate data representations, resulting in accurate classification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by NIH grant 2R42AG053149-02A1 and NSF grant DMS-2053170.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used (or will use) ONLY openly available human data that were originally located at Alzheimer's Disease Neuroimaging Initiative (ADNI).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at ADNI (https://adni.loni.usc.edu).